Market Overview

UPDATE: Oppenheimer Raises PT on Regeneron Pharmaceuticals Following Results of VIVID & VISTA Studies

Share:
Related REGN
Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More
31 Stocks Moving In Thursday's Mid-Day Session
Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold (Seeking Alpha)

In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $300.00 to $310.00.

In the report, Oppenheimer noted, “Following up on its announcement of top-line results in July, REGN presented full results from its pivotal VIVID and VISTA studies for Eylea in diabetic macular edema (DME) at two conferences this past Friday. As expected, Eylea performed strongly in Phase III, with both Q4W and Q8W regimens delivering comparable efficacy to Lucentis. REGN reiterated its plans to file for approval in DME by year-end 2013 using the 12-month data. Given these positive data and our previous survey work (refer to our Aug '13 REGN initiation for details), we believe Eylea will be the favored anti-VEGF in DME.”

Regeneron Pharmaceuticals closed on Friday at $305.65.

Latest Ratings for REGN

DateFirmActionFromTo
Dec 2017Deutsche BankInitiates Coverage OnHold
Dec 2017CitigroupDowngradesBuyNeutral
Nov 2017BTIG ResearchMaintainsBuyBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: David Ferreiro OppenheimerAnalyst Color Price Target Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!